Skip to content

Month: October 2020

Kick-off of the NOAR network, the COST project dedicated to the development of alpha therapy

On 22 October 2020 in Brussels, the COST (COoperation in Science and Technology) project dedicated to the development of alpha
Lire la suite >

SIRIC ILIAD shares the progress of its research with its partners

The SIRIC ILIAD Partners and Patient Representatives Committee met on 11 September to present its mid-term review. On 11 September
Lire la suite >

Clinical trial: FICTIoN Cohort

FICTIoN Cohort: Radiomic analyses of 18FDG PET and correlation with histology Type of study: Single-centre study Pathology: Triple-negative breast cancer,
Lire la suite >

Telix – SIRIC ILIAD Collaboration: TLX102 multiple myeloma treatment receives FDA orphan drug designation

The TLX102 treatment, resulting from the collaboration between Telix Pharmaceuticals (Australia), Osaka University (Japan) and the SIRIC ILIAD nuclear medicine
Lire la suite >



Archives SIRIC 2018-2022